Aliases & Classifications for Peanut Allergy

MalaCards integrated aliases for Peanut Allergy:

Name: Peanut Allergy 12 14
Allergy to Peanuts 12 69
Peanut Allergic Reaction 12
Peanut Hypersensitivity 41
Allergies Peanut 51

Classifications:



External Ids:

Disease Ontology 12 DOID:4378
MeSH 41 D021183
SNOMED-CT 64 213021008 91935009
UMLS 69 C0559470

Summaries for Peanut Allergy

Disease Ontology : 12 A food allergy that is an allergy or hypersensitivity to dietary substances from peanuts causing an overreaction of the immune system which in a small percentage of people may lead to severe physical symptoms.

MalaCards based summary : Peanut Allergy, also known as allergy to peanuts, is related to nut allergy and food allergy. An important gene associated with Peanut Allergy is FLG (Filaggrin), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Nicotine and Progesterone have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and t cells, and related phenotypes are immune system and respiratory system

Wikipedia : 72 Peanut allergy is a type of food allergy to peanuts. It is different from tree nut allergies. Physical... more...

Related Diseases for Peanut Allergy

Diseases related to Peanut Allergy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 143)
# Related Disease Score Top Affiliating Genes
1 nut allergy 30.4 FLG IL13
2 food allergy 29.9 FLG IFNG IL10 IL13
3 allergic hypersensitivity disease 29.5 IFNG IGHE IL10 IL13
4 dermatitis 29.4 CCL22 FLG IFNG IGHE IL13
5 dermatitis, atopic 28.9 CCL22 FLG IFNG IGHE IL10 IL13
6 asthma 28.4 CCL22 FLG HLA-DQB1 HLA-DRB1 IFNG IGHE
7 limbic encephalitis with lgi1 antibodies 10.5 HLA-DQB1 HLA-DRB1
8 exercise-induced anaphylaxis 10.5 FLG IGHE
9 refractory celiac disease 10.5 HLA-DQB1 IFNG
10 berylliosis 10.5 HLA-DRB1 IFNG
11 metal allergy 10.5 HLA-DQB1 HLA-DRB1
12 focal epithelial hyperplasia 10.5 HLA-DQB1 HLA-DRB1
13 beryllium disease 10.4 HLA-DQB1 HLA-DRB1
14 lichen planopilaris 10.4 HLA-DQB1 HLA-DRB1
15 type ii mixed cryoglobulinemia 10.4 HLA-DQB1 HLA-DRB1
16 staphylococcal toxic shock syndrome 10.4 IFNG IGHE
17 idiopathic inflammatory myopathy 10.4 HLA-DQB1 HLA-DRB1
18 recurrent respiratory papillomatosis 10.4 HLA-DQB1 HLA-DRB1
19 autoimmune pancreatitis 10.4 HLA-DQB1 HLA-DRB1
20 eczema herpeticum 10.4 FLG IFNG
21 egg allergy 10.4 FLG IGHE
22 eosinophilia-myalgia syndrome 10.4 HLA-DRB1 IFNG
23 pityriasis rosea 10.4 HLA-DQB1 HLA-DRB1
24 lichen sclerosus 10.4 HLA-DQB1 HLA-DRB1
25 whipple disease 10.4 HLA-DQB1 HLA-DRB1
26 african tick-bite fever 10.4 IFNG IL13
27 hyperlucent lung 10.4 IFNG IL10
28 penicillin allergy 10.4 IFNG IL13
29 pediatric multiple sclerosis 10.4 HLA-DQB1 HLA-DRB1
30 osteonecrosis of the jaw 10.4 HLA-DQB1 HLA-DRB1
31 strongyloidiasis 10.4 IFNG IL13
32 cytomegalovirus retinitis 10.4 HLA-DQB1 IFNG
33 juvenile myasthenia gravis 10.4 HLA-DRB1 IL10
34 central nervous system vasculitis 10.4 HLA-DRB1 IFNG
35 hyper ige syndrome 10.4 IFNG IGHE
36 sporotrichosis 10.4 IFNG IL10
37 immune suppression 10.4 IFNG IL10
38 baylisascariasis 10.4 IFNG IL10
39 histoplasmosis 10.4 HLA-DRB1 IFNG
40 eosinophilic fasciitis 10.3 AHR IFNG
41 microscopic polyangiitis 10.3 HLA-DRB1 IL10
42 chronic graft versus host disease 10.3 IFNG IL10
43 idiopathic achalasia 10.3 HLA-DQB1 IL10
44 clonorchiasis 10.3 IFNG IL10
45 urinary schistosomiasis 10.3 IFNG IL13
46 pericardial tuberculosis 10.3 IFNG IL10
47 actinic prurigo 10.3 HLA-DRB1 IL13
48 tuberculoid leprosy 10.3 IFNG IL10
49 ascaridiasis 10.3 IL10 IL13
50 orofacial granulomatosis 10.3 IFNG IL10

Graphical network of the top 20 diseases related to Peanut Allergy:



Diseases related to Peanut Allergy

Symptoms & Phenotypes for Peanut Allergy

MGI Mouse Phenotypes related to Peanut Allergy:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.56 AHR CCL22 CD14 CXCL10 HLA-DQB1 IFNG
2 respiratory system MP:0005388 9.1 AHR CD14 HLA-DQB1 IFNG IL10 IL13

Drugs & Therapeutics for Peanut Allergy

Drugs for Peanut Allergy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 44)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicotine Approved Phase 4 54-11-5 89594 942
2
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
3 Neurotransmitter Agents Phase 4,Phase 2
4 Autonomic Agents Phase 4
5 Central Nervous System Stimulants Phase 4
6 Cholinergic Agents Phase 4
7 Hormone Antagonists Phase 4
8 Hormones Phase 4
9 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
10 Nicotinic Agonists Phase 4
11 Peripheral Nervous System Agents Phase 4
12 Progestins Phase 4
13 Antibodies Phase 3,Phase 2,Phase 1
14 Immunoglobulins Phase 3,Phase 2,Phase 1
15 Immunoglobulin E Phase 3,Phase 1,Phase 2
16 Vaccines Phase 3,Phase 1
17
Histamine Approved, Investigational Phase 2 51-45-6, 75614-87-8 774
18
Ketotifen Approved Phase 2 34580-13-7, 34580-14-8 3827
19
Omalizumab Approved, Investigational Phase 2,Phase 1 242138-07-4
20
Glycerol Approved, Investigational Phase 1, Phase 2 56-81-5 753
21
Benzocaine Approved, Investigational Phase 1, Phase 2 1994-09-7, 94-09-7 2337
22 tannic acid Approved, Nutraceutical Phase 1, Phase 2
23 Anti-Allergic Agents Phase 2,Phase 1
24 Antipruritics Phase 2
25 Dermatologic Agents Phase 2
26 Histamine Antagonists Phase 2
27 Histamine H1 Antagonists Phase 2
28
Histamine Phosphate Phase 2 51-74-1 65513
29 Anti-Asthmatic Agents Phase 2,Phase 1
30 Respiratory System Agents Phase 2,Phase 1
31 Protective Agents Phase 1, Phase 2
32 Pharmaceutical Solutions Phase 2,Phase 1
33
Phenol Approved, Experimental Phase 1 108-95-2 996
34
Nitric Oxide Approved 10102-43-9 145068
35 English walnut Approved, Nutraceutical
36 Proton pump inhibitors
37 Caseins
38 Chelating Agents
39 Antioxidants
40 Bronchodilator Agents
41 Endothelium-Dependent Relaxing Factors
42 Vasodilator Agents
43 Acidophilus Nutraceutical
44 Soy Bean Nutraceutical

Interventional clinical trials:

(show top 50) (show all 95)

# Name Status NCT ID Phase Drugs
1 Basophil Activation Test (BAT) Sensitivity in Child Food Allergy Recruiting NCT01966640 Phase 4
2 Progesterone and Brain Imaging Study Recruiting NCT01954966 Phase 4 Progesterone;Placebo
3 Peanut Oral Induction Tolerance in Peanut's Allergic Teenagers Unknown status NCT02046083 Phase 2, Phase 3 arachid
4 Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy Completed NCT02636699 Phase 3
5 ARTEMIS Peanut Allergy In Children Recruiting NCT03201003 Phase 3
6 PALISADE Follow-on Study (ARC004) Recruiting NCT02993107 Phase 3
7 AR101 Real-World Open-Label Extension Study Recruiting NCT03337542 Phase 3
8 Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) Active, not recruiting NCT02635776 Phase 3
9 Safety Study of Viaskin Peanut to Treat Peanut Allergy Active, not recruiting NCT02916446 Phase 3
10 Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children Active, not recruiting NCT03126227 Phase 3
11 Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age Active, not recruiting NCT03211247 Phase 3
12 Follow-up of the PEPITES Study to Evaluate Long-term Efficacy and Safety of Viaskin Peanut in Children Active, not recruiting NCT03013517 Phase 3 Viaskin Peanut 250µg
13 Long-term Safety Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008) Enrolling by invitation NCT03292484 Phase 3
14 Pilot Study to Evaluate the Effect of Ketotifen on the Adverse Events Associated With Peanut Desensitization Unknown status NCT01625715 Phase 2 Ketotifen
15 Treatment of Severe Peanut Allergy With Xolair (Omalizumab) and Oral Immunotherapy Unknown status NCT02402231 Phase 2 Omalizumab
16 The Effect of Extrinsic Factors on Food Allergy Unknown status NCT01429896 Phase 2
17 Therapeutic Effect of Chinese Herbal Medicine on Food Allergy Unknown status NCT00602160 Phase 2 FAHF-2 (TM)
18 Oral Immunotherapy (OIT) for Peanut Allergy Completed NCT00815035 Phase 2 Peanut OIT;Placebo
19 Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy Completed NCT01675882 Phase 2
20 A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy Completed NCT01084174 Phase 1, Phase 2 Peanut powder;Peanut extract;Placebo extract;Placebo powder
21 Oral Immunotherapy for Peanut Allergy (PMIT) Completed NCT00597675 Phase 2
22 Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy Completed NCT00932282 Phase 1, Phase 2 Peanut Oral Immunotherapy;Omalizumab
23 Epicutaneous Immunotherapy in Peanut Allergy in Children Completed NCT01197053 Phase 2
24 Omalizumab in the Treatment of Peanut Allergy Completed NCT00949078 Phase 2 omalizumab
25 Determining the Efficacy and Value of Immunotherapy on the Likelihood of Peanut Tolerance: The DEVIL Study Completed NCT00932828 Phase 1, Phase 2 Low Dose Peanut Protein;High Dose Peanut Protein
26 Xolair Enhances Oral Desensitization in Peanut Allergic Patients Completed NCT01290913 Phase 1, Phase 2 Omalizumab
27 A Randomized, Double-Blind Placebo-Controlled Peanut Sublingual Immunotherapy Trial Completed NCT00580606 Phase 1, Phase 2 Glycerinated peanut allergenic extract;Placebo for peanut extract (glycerin)
28 Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children Completed NCT01955109 Phase 2
29 Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT Completed NCT01987817 Phase 2
30 Persistence of Oral Tolerance to Peanut Completed NCT01366846 Phase 2
31 Promoting Tolerance to Peanut in High-Risk Children Completed NCT00329784 Phase 2
32 A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g Completed NCT00382148 Phase 2 omalizumab
33 Mechanisms of Desensitization During Peanut Oral Immunotherapy Completed NCT01814241 Phase 2 Open label peanut OIT
34 A Study of Sublingual Immunotherapy in Peanut-allergic Children Completed NCT00597727 Phase 2 Peanut SLIT;Placebo SLIT
35 Placebo-Controlled Study to Investigate ANB020 Activity in Adult Patients With Peanut Allergy Recruiting NCT02920021 Phase 2 ANB020;Placebo
36 Boiled Peanut Oral Immunotherapy for the Treatment of Peanut Allergy: a Pilot Study Active, not recruiting NCT02149719 Phase 2
37 Sublingual Immunotherapy for Peanut Allergy and Induction of Tolerance Active, not recruiting NCT01373242 Phase 1, Phase 2 Liquid peanut extract (Peanut SLIT)
38 The Peanut Oral Immunotherapy Study: Safety, Efficacy and Discovery Active, not recruiting NCT02103270 Phase 2 Peanut Protein 4,000mg;Oat Flour;Peanut Protein 300 mg
39 Peanut Epicutaneous Phase II Immunotherapy Clinical Trial Active, not recruiting NCT01904604 Phase 2
40 Peanut Oral Immunotherapy in Children Active, not recruiting NCT01867671 Phase 2
41 Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial Active, not recruiting NCT01781637 Phase 1, Phase 2 Omalizumab;placebo
42 Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using (CPNA) Peanut OIT Safety Follow-On Study Active, not recruiting NCT02198664 Phase 2
43 Tolerance Following Peanut Oral Immunotherapy Active, not recruiting NCT01750879 Phase 1, Phase 2 Peanut Flour;Oat Flour
44 FARE Peanut SLIT and Early Tolerance Induction Active, not recruiting NCT02304991 Phase 2 Liquid Peanut Extract;Placebo Glycerin SLIT
45 Salvage Peanut Oral Immunotherapy Study Not yet recruiting NCT03251508 Phase 1, Phase 2 Peanut OIT
46 The Safety and Efficacy of a Peanut Immunotherapy Dissolving Film for Peanut Allergy Suspended NCT01897077 Phase 1, Phase 2 Peanut Dissolving Film
47 Peanut Oral Immunotherapy (OIT) - Initial Pilot Study in Adults Terminated NCT01274429 Phase 1, Phase 2 Peanut flour
48 A Safety and Efficacy Study of Xolair in Peanut Allergy Terminated NCT00086606 Phase 2 Xolair (omalizumab)
49 Efficacy and Safety of 4 Doses of QGE031 in Patients 18-50 Years of Age With Peanut Allergy Withdrawn NCT01451450 Phase 2 QGE031;Placebo
50 Peanut Allergy Oral Immunotherapy Desensitization Unknown status NCT01601522 Phase 1

Search NIH Clinical Center for Peanut Allergy

Cochrane evidence based reviews: peanut hypersensitivity

Genetic Tests for Peanut Allergy

Anatomical Context for Peanut Allergy

MalaCards organs/tissues related to Peanut Allergy:

38
Testes, Brain, T Cells, Skin, Breast

Publications for Peanut Allergy

Articles related to Peanut Allergy:

(show top 50) (show all 116)
# Title Authors Year
1
The importance of reducing risk in peanut allergy: Current and future therapies. ( 29289463 )
2018
2
Timely focus on breast-feeding in the peanut allergy debate. ( 29395368 )
2018
3
Canadian genome-wide association study and meta-analysis confirm HLA as a risk factor for peanut allergy independent of asthma. ( 29325868 )
2018
4
Peanut Allergy: An Epidemiologic Analysis of a Large Database. ( 29246346 )
2018
5
Potential Pitfalls in Applying Screening Criteria in Infants at Risk of Peanut Allergy. ( 29352591 )
2018
6
Peanut allergy reduction in high-risk pediatric patients. ( 29438186 )
2018
7
Should Younger Siblings of Peanut Allergic Children Be Screened for Peanut Allergy? ( 29397371 )
2018
8
Oral Immunotherapy in Japanese Children with Anaphylactic Peanut Allergy. ( 29339650 )
2018
9
Allergen specificity of early peanut consumption and effect on development of allergic disease in the Learning Early About Peanut Allergy study cohort. ( 29097103 )
2017
10
Indole-3-carbinol, a plant nutrient and AhR-Ligand precursor, supports oral tolerance against OVA and improves peanut allergy symptoms in mice. ( 28666018 )
2017
11
Evolution of Guidelines on Peanut Allergy and Peanut Introduction in Infants: A Review. ( 27820622 )
2017
12
Effect of endotoxin and alum adjuvant vaccine on peanut allergy. ( 28927819 )
2017
13
The Benefits of New Guidelines to Prevent Peanut Allergy. ( 28562280 )
2017
14
Economic evaluation of epinephrine auto-injectors for peanut allergy. ( 28634019 )
2017
15
Academy Approves NIAID Addendum Guidelines for the Prevention of Peanut Allergy. ( 28449792 )
2017
16
Addendum Guidelines for the Prevention of Peanut Allergy in the United States: Summary of the National Institute of Allergy and Infectious Diseases-Sponsored Expert Panel. ( 28449793 )
2017
17
Addendum guidelines for the prevention of peanut allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases-sponsored expert panel. ( 28065278 )
2017
18
Peanut oleosins associated with severe peanut allergy-importance of lipophilic allergens for comprehensive allergy diagnostics. ( 28342912 )
2017
19
Addendum Guidelines for the Prevention of Peanut Allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases-Sponsored Expert Panel. ( 28054723 )
2017
20
US guidelines for the prevention of peanut allergy 2017. ( 29175880 )
2017
21
Skin Testing or sIgE Testing Is Necessary Before Early Introduction of Peanut for Prevention of Peanut Allergy: Pro-Con Debate. ( 28967547 )
2017
22
Guidelines for Children With Peanut Allergy. ( 28030748 )
2017
23
Peanut Allergy Prevention Starts in Infancy. ( 28333730 )
2017
24
Airway exposure initiates peanut allergy by involving the IL-1 pathway and T follicular helper cells in mice. ( 29247716 )
2017
25
Prediction of clinical peanut allergy status among children in Hamilton, Ontario using chart review data collected during 2012-2015. ( 28194191 )
2017
26
Evaluation of nanoparticles as oral vehicles for immunotherapy against experimental peanut allergy. ( 28965967 )
2017
27
Determination of Crucial Immunogenic Epitopes in Major Peanut Allergy Protein, Ara h2, via Novel Nanoallergen Platform. ( 28638052 )
2017
28
Implementing Primary Prevention for Peanut Allergy at a Population Level. ( 28192569 )
2017
29
Dose of allergens in a peanut snack (Bamba) associated with prevention of peanut allergy. ( 28709966 )
2017
30
Addendum guidelines for the prevention of peanut allergy in the United States: Summary of the National Institute of Allergy and Infectious Diseases-sponsored expert panel. ( 28054718 )
2017
31
Ara h2 levels in dust from homes of individuals with peanut allergy and individuals with peanut tolerance. ( 28441989 )
2017
32
Peanut Allergen Threshold Study (PATS): Novel single-dose oral food challenge study to validate eliciting doses in children with peanut allergy. ( 28238744 )
2017
33
Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial. ( 29092786 )
2017
34
Dose-time-response relationship in peanut allergy using a human model of passive cutaneous anaphylaxis. ( 28189335 )
2017
35
The efficacy of oral and subcutaneous antigen-specific immunotherapy in murine cow's milk- and peanut allergy models. ( 29021893 )
2017
36
Re: "Addendum guidelines for the prevention of peanut allergy in the United States: report of the National Institute of Allergy and Infectious Diseases-sponsored expert panel". ( 28390590 )
2017
37
A comparative study on basophil activation test, histamine release assay, and passive sensitization histamine release assay in the diagnosis of peanut allergy. ( 28686296 )
2017
38
Peanut allergy and isotretinoin: reply to McCarthy etA al. ( 28691221 )
2017
39
Peanut Allergy Prevention: Guidelines from the NIAID. ( 28762705 )
2017
40
Prediction of peanut allergy in adolescence by early childhood storage protein-specific IgE signatures: The BAMSE population-based birth cohort. ( 28192142 )
2017
41
Genome-wide association study and meta-analysis in multiple populations identifies new loci for peanut allergy and establishes C11orf30/EMSY as a genetic risk factor for food allergy. ( 29030101 )
2017
42
A humanized mouse model of anaphylactic peanut allergy. ( 27417025 )
2016
43
Investigation of peanut oral immunotherapy with CpG/peanut nanoparticles in a murine model of peanut allergy. ( 27130858 )
2016
44
Isotretinoin treatment in a patient with known peanut allergy and positive IgE test results for soybean. ( 27670093 )
2016
45
Understanding the feasibility and implications of implementing early peanut introduction for prevention of peanut allergy. ( 27260320 )
2016
46
Anti-hIgE gene therapy of peanut-induced anaphylaxis in a humanized murine model of peanut allergy. ( 27372563 )
2016
47
Genomewide association study of peanut allergy reproduces association with amino acid polymorphisms in HLA-DRB1. ( 27883235 )
2016
48
Oral immunotherapy for peanut allergy induces eosinophilic esophagitis: three pediatric case reports. ( 26888330 )
2016
49
Peanut allergy, anaphylaxis, adrenaline and exacerbations of asthma. ( 27893943 )
2016
50
A lurking threat: transfer of peanut allergy through peripheral blood stem cell transplantation. ( 26904156 )
2016

Variations for Peanut Allergy

Expression for Peanut Allergy

Search GEO for disease gene expression data for Peanut Allergy.

Pathways for Peanut Allergy

Pathways related to Peanut Allergy according to GeneCards Suite gene sharing:

(show all 32)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.83 CCL22 CD14 CXCL10 HLA-DQB1 HLA-DRB1 IFNG
2
Show member pathways
13.47 CCL22 CD14 CXCL10 IFNG IL10 IL13
3
Show member pathways
13.08 CCL22 CXCL10 HLA-DQB1 HLA-DRB1 IFNG IGHE
4
Show member pathways
12.71 HLA-DQB1 HLA-DRB1 IFNG IL10 IL13
5
Show member pathways
12.64 CXCL10 HLA-DQB1 HLA-DRB1 IFNG IL13
6
Show member pathways
12.47 HLA-DQB1 HLA-DRB1 IFNG IGHE IL10
7 12.43 CD14 CXCL10 IFNG IL10
8
Show member pathways
12.39 CD14 CXCL10 IFNG IL10
9
Show member pathways
12.2 IFNG IL10 IL13
10 12.17 HLA-DQB1 HLA-DRB1 IFNG IL10
11
Show member pathways
12.11 HLA-DQB1 HLA-DRB1 IFNG IL10
12
Show member pathways
12.04 CD14 CXCL10 IFNG
13
Show member pathways
12.02 IFNG IL10 IL13
14 12 CD14 HLA-DQB1 HLA-DRB1
15 11.97 CD14 HLA-DQB1 HLA-DRB1 IFNG IL10
16
Show member pathways
11.97 AHR HLA-DQB1 HLA-DRB1 IFNG IL10 IL13
17 11.87 CD14 IFNG IL10
18 11.79 CD14 HLA-DQB1 HLA-DRB1
19 11.79 CCL22 IGHE IL10 IL13
20 11.77 CD14 IFNG IL10
21 11.74 HLA-DQB1 HLA-DRB1 IFNG
22 11.64 CD14 IFNG IL10
23 11.61 AHR IFNG IL10 IL13
24 11.5 HLA-DQB1 HLA-DRB1 IL10
25 11.25 CCL22 CXCL10 IL10 IL13
26 11.18 AHR IFNG IL13
27 11.12 CCL22 IFNG IL10 IL13
28 11.1 HLA-DRB1 IFNG IL13
29 11.06 CCL22 CXCL10 IL10 IL13
30 11.05 IFNG IL10 IL13
31 10.85 CCL22 CXCL10 IL10 IL13
32 10.4 HLA-DRB1 IFNG IL10 IL13

GO Terms for Peanut Allergy

Cellular components related to Peanut Allergy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.73 CCL22 CD14 CXCL10 IFNG IL10 IL13
2 extracellular region GO:0005576 9.5 CCL22 CD14 CXCL10 IFNG IGHE IL10
3 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.32 HLA-DQB1 HLA-DRB1
4 MHC class II protein complex GO:0042613 9.16 HLA-DQB1 HLA-DRB1
5 external side of plasma membrane GO:0009897 9.02 CD14 CXCL10 HLA-DRB1 IGHE IL13

Biological processes related to Peanut Allergy according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.73 CCL22 CXCL10 IL10 IL13
2 cellular response to lipopolysaccharide GO:0071222 9.69 CD14 CXCL10 IL10
3 regulation of receptor activity GO:0010469 9.65 CCL22 CXCL10 IFNG IL10 IL13
4 response to virus GO:0009615 9.63 CCL22 CXCL10 IFNG
5 response to lipopolysaccharide GO:0032496 9.62 CD14 CXCL10 IL10 IL13
6 interferon-gamma-mediated signaling pathway GO:0060333 9.58 HLA-DQB1 HLA-DRB1 IFNG
7 negative regulation of endothelial cell apoptotic process GO:2000352 9.57 IL10 IL13
8 positive regulation of cytokine secretion GO:0050715 9.56 CD14 IL10
9 positive regulation of release of sequestered calcium ion into cytosol GO:0051281 9.55 CXCL10 IL13
10 negative regulation of interferon-gamma production GO:0032689 9.54 HLA-DRB1 IL10
11 positive regulation of macrophage activation GO:0043032 9.52 IL10 IL13
12 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.49 HLA-DQB1 HLA-DRB1
13 response to molecule of bacterial origin GO:0002237 9.48 CD14 IL10
14 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.37 HLA-DQB1 HLA-DRB1
15 inflammatory response GO:0006954 9.35 CCL22 CD14 CXCL10 IL10 IL13
16 immune response GO:0006955 9.23 CCL22 CXCL10 HLA-DQB1 HLA-DRB1 IFNG IGHE
17 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 9.16 HLA-DQB1 HLA-DRB1

Molecular functions related to Peanut Allergy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide antigen binding GO:0042605 9.16 HLA-DQB1 HLA-DRB1
2 cytokine activity GO:0005125 9.02 CCL22 CXCL10 IFNG IL10 IL13
3 MHC class II receptor activity GO:0032395 8.96 HLA-DQB1 HLA-DRB1

Sources for Peanut Allergy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....